New gel shows promise for rosacea Flare-Ups
NCT ID NCT04886739
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a topical gel called CGB-400 in 78 adults with moderate to severe rosacea. Participants applied the gel or a placebo twice daily for 12 weeks. Researchers counted inflammatory lesions and assessed skin clarity to see if the gel reduces symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CGB-400 topical gel
What this could lead to
If it works, this could offer a new topical option to reduce redness and bumps in people with rosacea.
What could go wrong
This is a small, early-phase proof-of-concept study. The gel may not work better than a placebo, and results may not apply to all rosacea patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ROSACEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cage Bio Investigative Site 1
Fremont, California, 94538, United States